Study of Mavoglurants Effects on Alcohol Craving and Drinking in Adults with Alcohol Use Disorder Ages 21 to 50

What this Trial Is About

Researchers are studying how the drug mavoglurant affects alcohol craving and drinking in heavy drinkers with Alcohol Use Disorder AUD. This study uses a double-blind, placebo-controlled design to compare the effects of mavoglurant and placebo on alcohol consumption and cravings. The goal is to understand how mavoglurant influences drinking behavior and subjective responses in non-treatment seeking individuals with moderate or severe AUD. Participants will take part in two lab sessions, each preceded by a single dose of either 200 mg mavoglurant or a matching placebo. The sessions include a Cue Exposure Paradigm to measure craving and an Alcohol Drinking Paradigm to observe drinking behavior. The order of drug and placebo is randomized, with a 5 to 8 day washout period between sessions to clear the drug from the body. After the lab sessions, participants will have follow-up appointments at one week and one month. During the study, participants will be assessed on changes in the number of drinks consumed and their craving for alcohol during each lab session. The study includes questionnaires and structured clinical interviews to evaluate psychiatric status and drinking behavior. Safety labs and urine drug screens are monitored. The total participation involves two lab visits plus two follow-up visits over approximately one month, with careful monitoring throughout the study.

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers